Pfizer Inc. (PFE) — closed signal from December 15, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 15, 2026.
Predicted vs. what happened
What happened
Reached 44% of the predicted growth at its peak, without hitting the target.
The thesis — published December 15, 2025
Pfizer looks like a safer, steady pharma company that suddenly saw a surge of buying. A licensing deal announced 12/15 with Adaptive could bring payments near $890M and meaningfully widen what Pfizer can develop. The buying looks strong right now, but underlying business metrics are weak, so treat this as a short-term trade and keep tight limits on losses.
Primary drivers
- Licensing deals could bring up to about $890M and broaden the pipeline
- Sudden buying interest with lots more buyers than usual supports the move
- Stable pharmaceutical business may attract money when markets are risky
- Rally driven by headlines despite weak fundamentals increases reversal risk
How it played out
PFE: target not reached inside the window
Lyra published PFE at $26.32 on 2025-12-15 with a short-term thesis for 14% expected growth. The thesis pointed to licensing deals worth up to about $890M, stronger than usual buying interest, a stable pharmaceutical business, and reversal risk because the rally depended on headlines while fundamentals looked weak.
Inside the window, PFE rose but did not reach $30. The peak was $27.94 on 2026-02-11, a 6.2% gain. It ended at $26.58 on 2026-03-15. The thesis partially played out because the stock moved up, but the published target was missed. It never got there.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.